| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Triamterene (formerly SKF-8542; SKF8542; BRN-0266723; Dyrenium; Diucelpin; Diurene) is a diuretic commonly used in combination with thiazide diuretics (e.g. hydrochlorothiazide/triamterene) for the treatment of high blood pressure or swelling. Triamterene has potassium sparing properties, and also blocks Na+ channel (ENaC) in a voltage-dependent manner with an IC50 of 4.5 μM.
| ln Vitro |
Triamterene is cytotoxic to HCT116 and CT26 cells, with IC50 values of 31.30 and 24.45 μM [5]. Triamterene (100 and 200 µM, 2 hours) promotes lysosomal rupture, lowers lysosomal integrity, and triggers lysis in HepG2 cells [6]. Triamterene (10-100 µM) suppresses delayed rectifier potassium currents in guinea pig ventricular myocytes [7].
|
||
|---|---|---|---|
| ln Vivo |
In addition to intravenous pentylenetetrazole (PTZ) (0.5%, 1 mL/min), intraperitoneal PTZ (85 mg/kg), and maximal shock seizures (shown anticonvulsant efficacy in a rat model of MES)-induced convulsions, trimeterene (10–40 mg/kg/day PO, 5 days) is administered [3]. In awake saline rats, triamterene (25 mg/kg) lowers urine magnesium excretion [4].
|
||
| Cell Assay |
Immunofluorescence[6]
Cell Types: HepG2 cells Tested Concentrations: 100 and 200 µM Incubation Duration: 2 h Experimental Results: Induced Gal3-puncta formation. Induced the translocation of TFEB to the nucleus from the cytosol. |
||
| Animal Protocol |
|
||
| References |
[1]. Busch, A.E., et al., Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis. Pflugers Arch, 1996. 432(5): p. 760-6.
[2]. Gilfrich, H.J., et al., Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. Eur J Clin Pharmacol, 1983. 25(2): p. 237-41. [3]. Shafaroodi H, et al. A role for ATP-sensitive potassium channels in the anticonvulsant effects of triamterene in mice. Epilepsy Res. 2016 Mar;121:8-13. [4]. Devane J, et al. The effects of amiloride and triamterene on urinary magnesium excretion in conscious saline-loaded rats. Br J Pharmacol. 1981 Feb;72(2):285-9. [5]. Moghadam NH, et al. In vitro cytotoxicity and DNA/HSA interaction study of triamterene using molecular modelling and multi-spectroscopic methods. J Biomol Struct Dyn. 2019 Jun;37(9):2242-2253. [6]. Park NY, et al. Triamterene induces autophagic degradation of lysosome by exacerbating lysosomal integrity. Arch Pharm Res. 2021 Jun;44(6):621-631. [7]. Daleau P, et al. Triamterene inhibits the delayed rectifier potassium current (IK) in guinea pig ventricular myocytes. Circ Res. 1994 Jun;74(6):1114-20. |
| Molecular Formula |
C12H11N7
|
|
|---|---|---|
| Molecular Weight |
253.26
|
|
| CAS # |
396-01-0
|
|
| Related CAS # |
Triamterene (Standard);396-01-0;Triamterene-d5;1189922-23-3
|
|
| SMILES |
N1C2=C(N([H])[H])N=C(N([H])[H])N=C2N=C(C=1C1C([H])=C([H])C([H])=C([H])C=1[H])N([H])[H]
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9485 mL | 19.7426 mL | 39.4851 mL | |
| 5 mM | 0.7897 mL | 3.9485 mL | 7.8970 mL | |
| 10 mM | 0.3949 mL | 1.9743 mL | 3.9485 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA